Ce qui est en développement clinique pour les virus Bundibugyo et Sudan. Aucun de ces candidats n'est approuvé. Tracker uniquement, pas guide de disponibilité clinique.
Last updated
Important
Aucun produit médical approuvé n'est listé sur cette page.
Tous les candidats listés ici sont à l'étude. Certains sont en essais
cliniques, d'autres pré-cliniques, un ou deux sont stockés en vue d'une
autorisation d'urgence sous protocoles WHO R&D Blueprint. Aucun n'est
disponible pour usage clinique routinier. Cette page existe pour donner
aux journalistes, personnels de santé publique et chercheurs un
instantané du pipeline, et non comme directive clinique.
Référence éditoriale, pas un avis médical. En cas d'exposition possible au virus Ebola, contactez votre autorité sanitaire locale.
Candidats virus Bundibugyo (BDBV)
La souche derrière l'USPPI active de 2026. Pipeline plus restreint que pour Zaïre ou Sudan.
cAd3-BDBV (BDBV-specific candidate)
Pré-cliniquevaccin
NIAID Vaccine Research Center · Cible : BDBV
Mécanisme. Chimpanzee adenovirus type 3 vector encoding the Bundibugyo virus glycoprotein. The platform mirrors cAd3-EBO Z (Zaire) and cAd3-EBO S (Sudan).
État. Reported in pre-clinical animal studies. No human trials of a BDBV-specific cAd3 candidate are listed on ClinicalTrials.gov as of May 2026. Filovirus glycoprotein cross-reactivity may permit Phase 1 acceleration if WHO declares emergency-use scientific priority.
Mécanisme. Monoclonal antibody products approved as Ebanga (mAb114, ansuvimab) and Inmazeb (REGN-EB3) for Zaire ebolavirus. Pre-clinical cross-reactivity work has examined activity against BDBV glycoprotein with mixed results.
État. Neither product is approved for Bundibugyo. Cross-strain neutralisation has been observed in some in-vitro and animal studies; the regulatory and clinical path to expanded indication remains slow. Emergency-use protocols during a PHEIC could permit off-label evaluation under research authorisation.
SUDV a causé plusieurs épidémies depuis 1976. Deux candidats distincts ont atteint des données de Phase 2 d'immunogénicité avant l'épidémie de Mubende 2022.
cAd3-EBO S
Phase 2vaccin
Sabin Vaccine Institute, NIAID, with academic partners · Cible : SUDV
Mécanisme. Chimpanzee adenovirus type 3 (cAd3) vector encoding the Sudan ebolavirus glycoprotein. Single-dose intramuscular regimen under investigation.
État. Phase 2 immunogenicity data published. Sabin produced doses staged for emergency deployment to the 2022-2023 Uganda Mubende SUDV outbreak; the outbreak resolved before randomised efficacy data could be collected.
Mécanisme. Recombinant vesicular stomatitis virus (rVSV) platform analogous to Ervebo, expressing the Sudan ebolavirus glycoprotein in place of Zaire. Single dose under investigation.
État. In Phase 1/2 trials. Candidate is part of the WHO Solidarity Trial framework that would deploy multiple SUDV vaccine candidates head-to-head during an outbreak.
Bavarian Nordic + Janssen · Cible : EBOV, SUDV, MARV
Mécanisme. Modified vaccinia Ankara (MVA-BN) vector encoding glycoproteins from multiple filoviruses. Currently fielded as the Mvabea boost component of the approved Zabdeno + Mvabea Zaire vaccine, but also under study as a standalone heterologous boost or multivalent product.
État. Multivalent filovirus candidate. Has shown immunogenicity across multiple ebolavirus species in Phase 1 and 2 studies. Not licensed as a standalone product.
Plateformes ciblant plusieurs espèces ou en cours d'études de réactivité croisée.
MVA-BN-Filo (multivalent boost)
Phase 2vaccin
Bavarian Nordic + Janssen · Cible : EBOV, SUDV, MARV
Mécanisme. Modified vaccinia Ankara (MVA-BN) vector encoding glycoproteins from multiple filoviruses. Currently fielded as the Mvabea boost component of the approved Zabdeno + Mvabea Zaire vaccine, but also under study as a standalone heterologous boost or multivalent product.
État. Multivalent filovirus candidate. Has shown immunogenicity across multiple ebolavirus species in Phase 1 and 2 studies. Not licensed as a standalone product.
Mécanisme. Monoclonal antibody products approved as Ebanga (mAb114, ansuvimab) and Inmazeb (REGN-EB3) for Zaire ebolavirus. Pre-clinical cross-reactivity work has examined activity against BDBV glycoprotein with mixed results.
État. Neither product is approved for Bundibugyo. Cross-strain neutralisation has been observed in some in-vitro and animal studies; the regulatory and clinical path to expanded indication remains slow. Emergency-use protocols during a PHEIC could permit off-label evaluation under research authorisation.
